CRISPR THERAPEUTICS AG Other Non-Current Liabilities
CRISPR THERAPEUTICS AG (CRSP) had Other Non-Current Liabilities of $6.22 million as of 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OtherLiabilitiesNoncurrent · last filed 2026-08-03
- 2026-06-30: Other Liabilities, Noncurrent $6.22M.
- 2026-03-31: Other Liabilities, Noncurrent $5.95M.
- 2025-12-31: Other Liabilities, Noncurrent $6.14M.
- 2025-09-30: Other Liabilities, Noncurrent $5.28M.
| Period end | Other Liabilities, Noncurrent | Other Liabilities, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $6.22M 10-Q · filed 2026-08-03 | |
| 2026-03-31 | $5.95M 10-Q · filed 2026-05-04 | |
| 2025-12-31 | $6.14M 10-Q · filed 2026-08-03 | |
| 2025-09-30 | $5.28M 10-Q · filed 2025-11-10 | |
| 2025-06-30 | $4.48M 10-Q · filed 2025-08-04 | |
| 2025-03-31 | $3.32M 10-Q · filed 2025-05-06 | |
| 2024-12-31 | $3.44M 10-K · filed 2026-02-12 | |
| 2024-09-30 | $3.68M 10-Q · filed 2024-11-05 | |
| 2024-06-30 | $3.65M 10-Q · filed 2024-08-05 | |
| 2024-03-31 | $3.62M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $958.00K 10-K · filed 2025-02-11 | |
| 2023-09-30 | $5.39M 10-Q · filed 2023-11-06 | |
| 2023-06-30 | $5.48M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $5.80M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | $5.97M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $5.31M 10-Q · filed 2022-11-01 | |
| 2022-06-30 | $6.09M 10-Q · filed 2022-08-08 | |
| 2022-03-31 | $7.33M 10-Q · filed 2022-05-09 | |
| 2021-12-31 | $7.34M 10-K · filed 2023-02-21 | |
| 2021-09-30 | $8.09M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $8.70M 10-Q · filed 2021-07-29 | |
| 2021-03-31 | $8.14M 10-Q · filed 2021-04-27 | |
| 2020-12-31 | $7.63M 10-K · filed 2022-02-15 | |
| 2020-09-30 | $7.22M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $9.26M 10-Q · filed 2020-07-27 | |
| 2020-03-31 | $11.95M 10-Q · filed 2020-04-28 | |
| 2019-12-31 | $14.39M 10-K · filed 2021-02-16 | |
| 2019-09-30 | $235.00K 10-Q · filed 2019-10-28 | |
| 2019-06-30 | $220.00K 10-Q · filed 2019-07-29 | |
| 2019-03-31 | $182.00K 10-Q · filed 2019-04-29 | |
| 2018-12-31 | $243.00K 10-K · filed 2020-02-12 | |
| 2018-09-30 | $273.00K 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $283.00K 10-Q · filed 2018-08-07 | |
| 2018-03-31 | $298.00K 10-Q · filed 2018-05-08 | |
| 2017-12-31 | $314.00K 10-K · filed 2019-02-25 | |
| 2017-09-30 | $175.00K 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $198.00K 10-Q · filed 2017-08-10 | |
| 2017-03-31 | $177.00K 10-Q · filed 2017-05-11 | |
| 2016-12-31 | $189.00K 10-K · filed 2018-03-08 | |
| 2016-09-30 | $574.00K 10-Q · filed 2016-11-22 | |
| 2015-12-31 | $281.00K 10-K · filed 2017-03-10 | $445.00K 10-Q · filed 2016-11-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |